Fate Therapeutics (FATE) Change in Acquisitions & Divestments (2016 - 2026)
Fate Therapeutics (FATE) posted Change in Acquisitions & Divestments of $52.6 million for Q1 2026, down 20.75% on a QoQ basis from $66.3 million in Q4 2025, and down 43.18% year-over-year from $92.5 million in Q1 2025.
Fate Therapeutics (FATE) Change in Acquisitions & Divestments (2016 - 2026) Analysis & Trends
Fate Therapeutics' Change in Acquisitions & Divestments history runs 11 years deep, the most recent figure standing at $52.6 million for Q1 2026.
- Quarterly Change in Acquisitions & Divestments fell 43.18% year-over-year to $52.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $272.0 million (down 14.87% YoY) and the FY2025 annual result came in at $311.9 million, down 5.68% from the prior year.
- Change in Acquisitions & Divestments was $52.6 million for Q1 2026 at Fate Therapeutics, down from $66.3 million in the prior quarter.
- Across five years, Change in Acquisitions & Divestments topped out at $190.6 million in Q3 2022 and bottomed at $52.6 million in Q1 2026.
- A 5-year average of $104.7 million and a median of $95.5 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
- Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments soared 118.1% — and 2026, when it slumped 43.18%.
- Fate Therapeutics' Change in Acquisitions & Divestments stood at $166.9 million in 2022, then slumped by 42.78% to $95.5 million in 2023, then slumped by 36.21% to $60.9 million in 2024, then increased by 8.86% to $66.3 million in 2025, then slipped by 20.75% to $52.6 million in 2026.
- Business Quant data shows FATE's Change in Acquisitions & Divestments at $52.6 million in Q1 2026, $66.3 million in Q4 2025, and $81.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - |
| 2 | Nanobiotix | 1,880.51 Bn | 1,880.45 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 467.94 Bn | 463.15 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.63 Bn | 115.38 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.54 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.81 Bn | 62.81 Bn | - |
| 8 | Argenx Se | 55.78 Bn | 50.59 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn |
| 10 | Fate Therapeutics | 289.27 Mn | 289.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 52.56 Mn |
| Mar 31, 2026 | 52.56 Mn |
| Dec 31, 2025 | 66.32 Mn |
| Dec 31, 2025 | 66.32 Mn |
| Sep 30, 2025 | 81.45 Mn |
| Sep 30, 2025 | 81.45 Mn |
| Jun 30, 2025 | 71.64 Mn |
| Jun 30, 2025 | 71.64 Mn |
| Mar 31, 2025 | 92.49 Mn |
| Mar 31, 2025 | 92.49 Mn |
| Dec 31, 2024 | 60.92 Mn |
| Dec 31, 2024 | 60.92 Mn |
| Sep 30, 2024 | 90.70 Mn |
| Sep 30, 2024 | 90.70 Mn |
| Jun 30, 2024 | 75.34 Mn |
| Jun 30, 2024 | 75.34 Mn |
| Mar 31, 2024 | 103.74 Mn |
| Mar 31, 2024 | 103.74 Mn |
| Dec 31, 2023 | 95.50 Mn |
| Dec 31, 2023 | 95.50 Mn |